Pancreatic Cancer Research

ResearcherKagoshima UniversityNo recent work listed

Shoji Natsugoe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3171-7149; OpenAlex author ID A5063331240, A5101083745, A5110043316. Sources: OpenAlex.

Their work

Papers
36 (first author 0, last author 25)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2011: 3 papers · 2012: 6 papers · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 7 papers · 2018: 5 papers · 2019: 4 papers · 2020: 1 paper

Papers 36

  1. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. Last author DOI 10.1016/j.pan.2019.11.015↗
  2. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  3. Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8. Last author DOI 10.1038/s10038-019-0584-6↗
  4. Significance of 18F-Fluorodeoxyglucose (FDG) Uptake in Response to Chemoradiotherapy for Pancreatic Cancer. Last author DOI 10.1245/s10434-018-07098-6↗
  5. Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation. Last author DOI 10.3390/cancers11030327↗
  6. Corrigendum to "Clinical impact of circulating tumor cells and therapy response in pancreatic cancer" [43 (6) (2017) 1050-1055]. Last author DOI 10.1016/j.ejso.2018.03.015↗
  7. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. Last author DOI 10.1097/mpa.0000000000001066↗
  8. Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. Last author DOI 10.1111/cas.13610↗
  9. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-018-6357-1↗
  10. Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3… Last author DOI 10.18632/oncotarget.25599↗
  11. Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. Co-author DOI 10.1007/s10585-017-9840-3↗
  12. Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. Last author DOI 10.1016/j.ejso.2017.01.241↗
  13. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. Last author DOI 10.1016/j.pan.2017.07.191↗
  14. MicroRNA in pancreatic cancer. Last author DOI 10.1038/jhg.2016.59↗
  15. ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/cas.13119↗
  16. Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.18261↗
  17. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Last author DOI 10.18632/oncotarget.19591↗
  18. Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Co-author DOI 10.1002/ijc.30110↗
  19. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. Last author DOI 10.1007/s00268-016-3477-2↗
  20. miR-30 family promotes migratory and invasive abilities in CD133(+) pancreatic cancer stem-like cells. Co-author DOI 10.1007/s13577-016-0137-7↗
  21. CD133 Modulate HIF-1α Expression under Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells. Co-author DOI 10.3390/ijms17071025↗
  22. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Last author DOI 10.1016/j.pan.2015.09.015↗
  23. Assessment of percutaneous laparoscopic ultrasonography-guided core needle biopsy for the advanced diagnosis of unresectable pancreatic cancer. Last author DOI 10.6092/1590-8577/2891↗
  24. [Radiotherapy for metastatic lesion of pancreatic cancer]. Last author PMID 25857007↗
  25. Hypoxia inducible factor-1 alpha plays a pivotal role in hepatic metastasis of pancreatic cancer: an immunohistochemical study. Co-author DOI 10.1002/jhbp.6↗
  26. M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pa… Last author DOI 10.1097/mpa.0b013e318254f2d1↗
  27. [Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy]. Last author PMID 24393873↗
  28. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. Last author DOI 10.1002/jso.23020↗
  29. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. Co-author DOI 10.1007/s00534-011-0400-y↗
  30. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic c… Co-author DOI 10.1007/s13577-011-0037-9↗
  31. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. Co-author DOI 10.1111/j.1349-7006.2012.02235.x↗
  32. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Last author DOI 10.1245/s10434-012-2263-0↗
  33. [A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy]. Last author PMID 22421785↗
  34. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. Co-author DOI 10.1016/j.jss.2009.05.026↗
  35. Advanced staging laparoscopy using single-incision approach for unresectable pancreatic cancer. Last author DOI 10.1097/sle.0b013e31823bae57↗
  36. microRNA-10b: a new marker or the marker of pancreatic ductal adenocarcinoma? Co-author DOI 10.1158/1078-0432.ccr-11-1477↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroshi Kurahara · 30 shared papers, 2011–2020 · strength 1.80
  2. Kosei Maemura · 26 shared papers, 2011–2020 · strength 1.55
  3. Yuko Mataki · 26 shared papers, 2011–2020 · strength 1.47
  4. Tetsuya Idichi · 8 shared papers, 2017–2020 · strength 0.60
  5. Sonshin Takao · 15 shared papers, 2011–2016 · strength 0.56
  6. Hiroyuki Shinchi · 10 shared papers, 2012–2020 · strength 0.55
  7. Naohiko Seki · 7 shared papers, 2017–2019 · strength 0.50
  8. Haruhi Fukuhisa · 4 shared papers, 2018–2019 · strength 0.31
  9. Qiang Ding · 7 shared papers, 2012–2016 · strength 0.29
  10. Keiichi Yonemori · 4 shared papers, 2017 · strength 0.29
  11. Koki Maeda · 6 shared papers, 2012–2016 · strength 0.21
  12. Yumi Miyazaki · 4 shared papers, 2012–2016 · strength 0.19
  13. Tomomi Hayashi · 4 shared papers, 2011–2016 · strength 0.14
  14. K. Okubo · 2 shared papers, 2017–2018 · strength 0.14
  15. Danny R. Welch · 2 shared papers, 2016–2017 · strength 0.14
  16. Michiyo Higashi · 2 shared papers, 2013–2020 · strength 0.13
  17. Koichiro Tsukasa · 2 shared papers, 2016 · strength 0.13
  18. Shyuichiro Matsubara · 2 shared papers, 2012–2016 · strength 0.10
  19. Muhammad Khalid · 1 shared paper, 2019 · strength 0.08
  20. Eric D Young · 1 shared paper, 2017 · strength 0.08
  21. Ken Sasaki · 1 shared paper, 2017 · strength 0.08
  22. Taketo Matsunaga · 1 shared paper, 2019 · strength 0.07
  23. Akira Chikamoto · 1 shared paper, 2019 · strength 0.07
  24. Kazuyoshi Nishihara · 1 shared paper, 2019 · strength 0.07
  25. Yusuke Watanabe · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.